Beauty Health Q4 revenue beats estimates, stock falls on weak guidance

Published 12/03/2025, 21:44
Beauty Health Q4 revenue beats estimates, stock falls on weak guidance

LONG BEACH, Calif. - The Beauty Health Company (NASDAQ:SKIN) reported fourth-quarter 2024 results that exceeded analyst expectations for revenue, but the stock fell 2.9% as the company provided weak guidance for the upcoming year.

The maker of Hydrafacial skincare devices posted revenue of $83.5 million for the quarter, surpassing the consensus estimate of $77.39 million. This represents a 13.8% decrease compared to the same quarter last year. The company reported an adjusted loss per share of $0.08, which was better than the analyst estimate of a $0.11 loss.

Beauty Health’s consumables net sales increased to $56.7 million from $52.2 million YoY, while delivery systems net sales declined to $26.8 million from $44.6 million. The company ended the year with an estimated active install base of 34,735 units, up from 31,446 in the prior year.

CEO Marla Beck commented, "In Q4 2024, we continued to strengthen our financial position, exceeding the high end of our guidance for both net sales and adjusted EBITDA."

Despite the revenue beat, Beauty Health’s stock declined following the earnings release, likely due to its weak guidance for 2025. The company expects full-year 2025 revenue between $270 million and $300 million, which is below the current year’s $334.3 million and analyst expectations of $332.5 million. Adjusted EBITDA for 2025 is projected to be between $10 million and $25 million.

The company cited near-term global macroeconomic uncertainty and industry headwinds as factors affecting its outlook. Beauty Health is focusing on deepening partnerships, accelerating innovations, and enhancing commercial execution to drive long-term shareholder value.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.